Ismar Lima Cavalcanti , Estêvão Luiz Carvalho Braga , Nubia Verçosa , Alberto Schanaider , Louis Barrucand , Hans Donald de Boer , Luiz Vane
{"title":"Efeitos do rocurônio, sugamadex e complexo rocurônio‐sugamadex sobre a coagulação em ratos","authors":"Ismar Lima Cavalcanti , Estêvão Luiz Carvalho Braga , Nubia Verçosa , Alberto Schanaider , Louis Barrucand , Hans Donald de Boer , Luiz Vane","doi":"10.1016/j.bjan.2020.08.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objectives</h3><p>Sugammadex is an alternative pharmacological drug capable of reversing neuromuscular blockades without the limitations that are presented by anticholinesterase drugs. Coagulation disorders that are related to treatment with sugammadex were reported. The exact mechanism of the effects on coagulation are not fully understood. The objective of this research is to evaluate the effects of rocuronium, sugammadex and the rocuronium‐sugammadex complex on coagulation in an experimental model in rats.</p></div><div><h3>Methods</h3><p>This is an experimental randomized animal study. Wistar rats were randomly assigned into the following groups: the Control Group; the Ssal Group – 0.5 mL of intravenous saline; the Sugammadex Group – intravenous sugammadex (100 mg.kg<sup>‐1</sup>); and the Rocuronium‐Sugammadex Group – intravenous solution with rocuronium (3.75 mg.kg<sup>‐1</sup>) and sugammadex (100 mg.kg<sup>‐1</sup>). Anesthesia was performed by using isoflurane with controlled ventilation. Coagulation factors were measured 10 minutes after the end of the preoperative preparation and 30 minutes after the administration of the drugs in accordance with the chosen groups.</p></div><div><h3>Results</h3><p>Platelet counts, prothrombin times and activated partial thromboplastin times were similar between the groups and between the moments within each group. There were reductions in the plasma fibrinogen levels between sample times 1 and 2 in the Rocuronium‐Sugammadex group (<em>p</em> <!-->=<!--> <!-->0.035).</p></div><div><h3>Conclusions</h3><p>The rocuronium‐sugammadex complex promoted reductions in plasma fibrinogen counts, although the levels were still within normal limits.</p></div>","PeriodicalId":21261,"journal":{"name":"Revista brasileira de anestesiologia","volume":"70 6","pages":"Pages 635-641"},"PeriodicalIF":1.0000,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bjan.2020.08.007","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista brasileira de anestesiologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0034709420304372","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
Background and objectives
Sugammadex is an alternative pharmacological drug capable of reversing neuromuscular blockades without the limitations that are presented by anticholinesterase drugs. Coagulation disorders that are related to treatment with sugammadex were reported. The exact mechanism of the effects on coagulation are not fully understood. The objective of this research is to evaluate the effects of rocuronium, sugammadex and the rocuronium‐sugammadex complex on coagulation in an experimental model in rats.
Methods
This is an experimental randomized animal study. Wistar rats were randomly assigned into the following groups: the Control Group; the Ssal Group – 0.5 mL of intravenous saline; the Sugammadex Group – intravenous sugammadex (100 mg.kg‐1); and the Rocuronium‐Sugammadex Group – intravenous solution with rocuronium (3.75 mg.kg‐1) and sugammadex (100 mg.kg‐1). Anesthesia was performed by using isoflurane with controlled ventilation. Coagulation factors were measured 10 minutes after the end of the preoperative preparation and 30 minutes after the administration of the drugs in accordance with the chosen groups.
Results
Platelet counts, prothrombin times and activated partial thromboplastin times were similar between the groups and between the moments within each group. There were reductions in the plasma fibrinogen levels between sample times 1 and 2 in the Rocuronium‐Sugammadex group (p = 0.035).
Conclusions
The rocuronium‐sugammadex complex promoted reductions in plasma fibrinogen counts, although the levels were still within normal limits.
期刊介绍:
The Brazilian Journal of Anesthesiology is the official journal of the Brazilian Anesthesiology Society. It publishes articles classified into the following categories:
-Scientific articles (clinical or experimental trials)-
Clinical information (case reports)-
Reviews-
Letters to the Editor-
Editorials.
The journal focuses primarily on clinical trials, with scope on clinical practice, aiming at providing applied tools to the anesthesiologist and critical care physician.
The Brazilian Journal of Anesthesiology accepts articles exclusively forwarded to it. Articles already published in other journals are not accepted. All articles proposed for publication are previously submitted to the analysis of two or more members of the Editorial Board or other specialized consultants.